METFORMIN (M) AND PROPRANOLOL (P) ACT ON DIFFERENT STEPS OF THE METASTATIC CASCADE OF A TRIPLE NEGATIVE MURINE MAMMARY ADENOCARCINOMA

NAHUEL CESATTI LALUCE; O. GRACIELA SCHAROVSKY; MARÍA VIRGINIA BAGLIONI; MAINETTI LEANDRO; MAURICIO MENACHO MÁRQUEZ; ANSELMINO LUCIANO; VIVIANA R. ROZADOS; MARÍA JOSÉ RICO; NAHUEL CESATTI LALUCE; O. GRACIELA SCHAROVSKY; MARÍA VIRGINIA BAGLIONI; MAINETTI LEANDRO; MAURICIO MENACHO MÁRQUEZ; ANSELMINO LUCIANO; VIVIANA R. ROZADOS; MARÍA JOSÉ RICO

Mar del Plata

Congreso; Reunión Anual de Biociencia 2019; 2019

Sociedad Argentina de Investigación Clínica (SAIC)

Drug repositioning in oncology refers tothe application of drugs designed for other uses that showedantitumor effect. Metformin is an antidiabetic drug andpropranolol is a ß-blocker. We have reported that M+P treatmentreduced tumor growth and lung metastases development in twotriple negative mammary tumor models. Also, we found thatM+P combination showed a potential adjuvant effect in both invivo models. To further deepen our studies, we aimed to explorethe effect of M+P on different events of the metastatic cascade intriple negative 4T1 mouse tumor model. We extracted bloodfrom BALB/c mice bearing tumors in the exponential growthphase of: C (control) and M+P [treated with M (2g/l) + P(25mg/l)] groups. A lower percentage of epithelial cells wasfound in M+P group (flow cytometry, p= 0.06). To characterizesurvival and extravasation of circulating tumor cells, mice werei.v inoculated with 5x104 green tracker labeled cells and treatedas C or M+P. After 2 days, M+P group showed lower percentageof circulating tumor cells (p